InsiderClue
← All stocks

Zymeworks Inc.

ZYME Scheduled selling only
CIK 0001937653 #2095 in the set updated 18 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$4.67M
$0.00 on a plan · $4.67M straight out of an exercise
Sold at will
$0.00
0 of 10 sales
Net
−$4.67M
$0.00 against sales at will

By person

7 insiders · 10 transactions
7.8×

Kenneth Galbraith holds 7.8 times base salary in stock. $5.14M of shares against $654.83K in salary for 2024.

Salary from the company's own proxy. The shares are what Kenneth Galbraith last reported holding, valued at $22.67, the price Common Stock was last bought or sold at on the open market here, on 12 Jan 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Galbraith Kenneth
Chair & CEO
—
$3.34M (4) scheduled
−$3.34M
226,842
0.3197%
$5.14M
+854.6%
Moore Paul Andrew
Chief Scientific Officer
—
$721.46K (3) scheduled
−$721.46K
48,497
0.0683%
$1.10M
+558.3%
Smith Jeffrey T L
EVP & Chief Medical Officer
—
$475.56K (2) scheduled
−$475.56K
26,708
0.0376%
$605.56K
—
Hollywood Mark
EVP & Chief Operating Officer
—
$138.76K (1) scheduled
−$138.76K
133,852
0.1886%
$3.03M
+10.3%
EcoR1 Capital, LLC entity
Director
—
—
—
22,970,388
32.37%
$520.82M
+56.3%
Ciongoli Gregory Austin
Director
—
—
—
488,500
0.6884%
$11.08M
+564.6%
PATTERSON LEONE D
EVP, Chief Bus & Fin Officer
—
—
—
459
0.0006%
$10.41K
—

Individual transactions

10
Insider
Date
Role
Action
Shares
Price
Amount
Galbraith Kenneth
12 Jan 2026
Chair & CEO
Sold after exercise
30,424
$22.67
$689.82K
Moore Paul Andrew
12 Jan 2026
Chief Scientific Officer
Sold after exercise
9,560
$22.67
$216.76K
Smith Jeffrey T L
12 Jan 2026
EVP & Chief Medical Officer
Sold after exercise
9,310
$22.67
$211.09K
Hollywood Mark
12 Jan 2026
EVP & Chief Operating Officer
Sold after exercise
6,120
$22.67
$138.76K
Moore Paul Andrew
5 Jan 2026
Chief Scientific Officer
Sold after exercise
10,821
$25.10
$271.57K
Moore Paul Andrew
5 Jan 2026
Chief Scientific Officer
Sold after exercise
9,289
$25.10
$233.13K
Galbraith Kenneth
5 Jan 2026
Chair & CEO
Sold after exercise
31,686
$25.10
$795.22K
Galbraith Kenneth
5 Jan 2026
Chair & CEO
Sold after exercise
22,657
$25.10
$568.62K
Smith Jeffrey T L
5 Jan 2026
EVP & Chief Medical Officer
Sold after exercise
10,538
$25.10
$264.47K
Galbraith Kenneth
22 Dec 2025
Chair & CEO
Sold after exercise
47,528
$27.02
$1.28M

What was left out

Form 4 filings counted 21
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 10
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 389,898
History held since 17 Oct 2022